Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Definium Therapeutics Inc shares valued at $73,623 were sold by Karlin Daniel on Dec 26 ’25. At $13.15 per share, Karlin Daniel sold 5,600 shares. The insider’s holdings dropped to 425,025 shares worth approximately $6.38 million following the completion of this transaction.
Also, Barrow Robert sold 25,791 shares, netting a total of over 339,072 in proceeds. Following the sale of shares at $13.15 each, the insider now holds 778,477 shares.
Before that, Sullivan Mark had sold 11,276 shares from its account. In a trade valued at $148,244, the Chief Legal Officer traded Definium Therapeutics Inc shares for $13.15 each. Upon closing the transaction, the insider’s holdings decreased to 11,276 shares, worth approximately $4.24 million.
As published in their initiating research note from Needham on October 13, 2025, Definium Therapeutics Inc [MNMD] has been a Buy and the price target has been revised to $28. As of January 28, 2025, Evercore ISI has initiated its “an Outperform” rating for MNMD. Earlier on December 20, 2024, Chardan Capital Markets initiated its rating. Their recommendation was “a Buy” for MNMD stock.
Analyzing MNMD Stock Performance
On last trading session, Definium Therapeutics Inc [NASDAQ: MNMD] rose 1.01% to $15.02. The stock’s lowest price that day was $14.31, but it reached a high of $15.16 in the same session. During the last five days, there has been a surge of approximately 7.06%. Over the course of the year, Definium Therapeutics Inc shares have jumped approximately 131.25%.
Is Definium Therapeutics Inc subject to short interest?
Stocks of Definium Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 2.7 million shares to 15.05 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 12.35 million shares. A jump of 17.96% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.82 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.82.
Which companies own the most shares of Definium Therapeutics Inc (MNMD)?
In terms of Definium Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 28 in the next 12 months, up nearly 88.3% from the previous closing price of $14.87. Analysts anticipate Definium Therapeutics Inc stock to reach 28 by 2026, with the lowest price target being 28. In spite of this, 2 analysts ranked Definium Therapeutics Inc stock as Buy at the end of 2026. On October 14, 2024, Leerink Partners assigned a price target of “an Outperform” to the stock and resumed coverage with a $20.
